|Public on Sep 03, 2019
|The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress
|Expression profiling by high throughput sequencing
Expression profiling by array
|Lung cancer is the leading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite early surgical removal. Hypoxic regions within tumors represent sources of aggressiveness and resistance to therapy. While long non-coding RNAs (lncRNAs) are increasingly recognized as major gene expression regulators, their regulation and function following hypoxic stress are still largely unexplored. Combining profiling studies on early stage lung adenocarcinomas (LUAD) biopsies and on A549 LUAD cell lines cultured in normoxic or hypoxic conditions, we identified a subset of lncRNAs that are both correlated with the hypoxic status of tumors and regulated by hypoxia in vitro.
We focused on a new transcript, NLUCAT1 that is strongly upregulated by hypoxia in vitro and correlated with hypoxic markers and poor prognosis in LUADs. Full molecular characterization showed that NLUCAT1 is a large nuclear transcript composed of 6 exons and mainly regulated by NF-ĸB and NRF2 transcription factors. CRISPR-Cas9-mediated invalidation of NLUCAT1 revealed a decrease in proliferative and invasive properties, an increase in oxidative stress and a higher sensitivity to cisplatin-induced apoptosis. Transcriptome analysis of NLUCAT1-deficient cells showed repressed genes within the anti-oxidant and/or cisplatin-response networks. We demonstrated that the concomitant knockdown of 4 of these genes, GPX2, GLRX, ALDH3A1 and PDK4, significantly increased ROS-dependent caspase activation, thus partially mimicking the consequences of NLUCAT1 inactivation in LUAD cells.
Overall, we demonstrate that NLUCAT1 contributes to an aggressive phenotype in early-stage hypoxic tumors suggesting it may represent a new potential therapeutic target in LUADs.
This SuperSeries is composed of the SubSeries listed below.
|Refer to individual Series
|Rezzonico R, Nottet N, Mari B, Barbry P, Lebrigand K
|Jul 12, 2018
|Last update date
|Sep 05, 2019
|Functional Genomics Platform of Nice-Sophia-Antipolis, France.
|660 route des lucioles
|Valbonne - Sophia-Antipolis
|AB 5500 Genetic Analyzer (Homo sapiens)
|Agilent-039494 SurePrint G3 Human GE v2 8x60K Microarray 039381 (Probe Name version)
|Illumina NextSeq 500 (Homo sapiens)
|This SuperSeries is composed of the following SubSeries:
|Transcriptome profiling of 57 LUAD samples and 11 peritumoral normal lung tissues
|Impact of NLUCAT1 deletion on A549 cells in normoxic and hypoxic conditions
|Hypoxic transcriptomic signature of A549 cells (Agilent microarrays)